[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Zee C O N T R A R I A N [@ZeeContrarian1](/creator/twitter/ZeeContrarian1) on x 28.7K followers Created: 2025-07-07 19:21:48 UTC Biotech Corner - $KSNA KNSA’s ARCALYST is an infusion treatment for the rare disease pericarditis, expected to generate $600M in sales this year and reach $1.2B by 2030. But here’s the catch: under a licensing agreement with Regeneron ( $REGN), $KNSA splits profits 50/50 with $REGN. This means the actual revenue attributable to KNSA is closer to $600M. The company is profitable, with an enterprise value (EV) of $1.76B. In terms of valuation, it’s trading at 3x peak sales and a 2029 P/E of 10x, in line with industry standards, so nothing too extreme. So, what’s the market missing? A lot. Here’s where it gets interesting: Let’s break it down. There are three assets the market is overlooking. 1.CD40 antibody for autoimmune indications: Post-Phase 2, and the company is actively looking to outlicense it to a larger partner. 2.OSMRβ antibody, licensed to Roche ( $ROG.VX): Currently in Phase X trials for ulcerative colitis (UC) (results due next year) and idiopathic pulmonary fibrosis (IPF) (results expected in 2027). But the third asset is the real game-changer: 3.A subcutaneous (SC) version of ARCALYST, in Phase X trials, compared to the existing intravenous (IV) version. Here’s the kicker: moving ARCALYST from IV to SC should dramatically increase sales. And more importantly… $KNSA owns the SC version outright, meaning no revenue-sharing with REGN. This alone should double the company’s valuation once analysts factor it into their models. Moreover, since ARCALYST is approaching the big pharma M&A threshold ($1B+ in peak sales), and $KNSA will retain XXX% of the profits from the new version, the company becomes a prime acquisition target. Interim results from the pivotal trial are expected in H2 2026, with final results in Q1 2028. The new version will likely hit the market by 2029. We’re bullish on this one, projecting a XX% upside.  XXXXXX engagements  **Related Topics** [$knsa](/topic/$knsa) [$regn](/topic/$regn) [$12b](/topic/$12b) [$600m](/topic/$600m) [$ksna](/topic/$ksna) [regeneron pharmaceuticals inc](/topic/regeneron-pharmaceuticals-inc) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/ZeeContrarian1/status/1942303050061996489)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Zee C O N T R A R I A N @ZeeContrarian1 on x 28.7K followers
Created: 2025-07-07 19:21:48 UTC
Biotech Corner - $KSNA
KNSA’s ARCALYST is an infusion treatment for the rare disease pericarditis, expected to generate $600M in sales this year and reach $1.2B by 2030.
But here’s the catch: under a licensing agreement with Regeneron ( $REGN), $KNSA splits profits 50/50 with $REGN.
This means the actual revenue attributable to KNSA is closer to $600M. The company is profitable, with an enterprise value (EV) of $1.76B.
In terms of valuation, it’s trading at 3x peak sales and a 2029 P/E of 10x, in line with industry standards, so nothing too extreme.
So, what’s the market missing?
A lot. Here’s where it gets interesting:
Let’s break it down. There are three assets the market is overlooking. 1.CD40 antibody for autoimmune indications: Post-Phase 2, and the company is actively looking to outlicense it to a larger partner. 2.OSMRβ antibody, licensed to Roche ( $ROG.VX): Currently in Phase X trials for ulcerative colitis (UC) (results due next year) and idiopathic pulmonary fibrosis (IPF) (results expected in 2027).
But the third asset is the real game-changer:
3.A subcutaneous (SC) version of ARCALYST, in Phase X trials, compared to the existing intravenous (IV) version.
Here’s the kicker: moving ARCALYST from IV to SC should dramatically increase sales. And more importantly…
$KNSA owns the SC version outright, meaning no revenue-sharing with REGN. This alone should double the company’s valuation once analysts factor it into their models.
Moreover, since ARCALYST is approaching the big pharma M&A threshold ($1B+ in peak sales), and $KNSA will retain XXX% of the profits from the new version, the company becomes a prime acquisition target.
Interim results from the pivotal trial are expected in H2 2026, with final results in Q1 2028. The new version will likely hit the market by 2029.
We’re bullish on this one, projecting a XX% upside.
XXXXXX engagements
Related Topics $knsa $regn $12b $600m $ksna regeneron pharmaceuticals inc stocks healthcare